**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 69128

**Manuscript Type:** ORIGINAL ARTICLE

***Randomized Controlled Trial***

**Zinc carnosine-based modified bismuth quadruple therapy *vs* standard triple therapy for *Helicobacter pylori* eradication: A randomized controlled study**

Ibrahim N *et al*. Zinc carnosine-based MBQT for *H. pylori* eradication

Nour Ibrahim, Hassan El Said, Ali Choukair

**Nour Ibrahim,** Faculty of Medical Sciences, Lebanese University, Beirut 0000, Lebanon

**Hassan El Said,** Department of Biological and Chemical Sciences, School of Arts and Sciences, Lebanese International University, Beirut 0000, Lebanon

**Ali Choukair,** Department of Gastroenterology, Clemenceau Medical Center, Dubai 00000, United Arab Emirates

**Author contributions:** Choukair A designed the study, collected the data and wrote the first draft of the manuscript; Ibrahim N analyzed the data and contributed to the manuscript writing; all authors critically revised the manuscript and read and approved the final version of the manuscript.

**Supported by** Synergy Group

**Corresponding author: Nour Ibrahim, MD, Research Fellow,** Faculty of Medical Sciences, Lebanese University, Old Saida Road Street, Hadath Area, Beirut 0000, Lebanon. nouribrahim5@hotmail.com

**Received:** June 25, 2021

**Revised:** August 7, 2021

**Accepted: November 26, 2021**

**Published online:**

**Abstract**

BACKGROUND

*Helicobacter pylori* (*H. pylori*) infection is a worldwide problem with increasing burden on the health sector due to its increasing rate of resistance. The conventional triple therapy (TT) is becoming obsolete with a high failure rate of eradication, necessitating the need for better alternatives or regimens.

AIM

To investigate *H. pylori* eradication rate of TT *vs* modified bismuth quadruple therapy.

METHODS

Ninety-two patients with dyspepsia symptoms and positive 13C-urea breath test were randomly assigned to two groups. The first group (control group) was treated for 14 d using standard TT protocol: Esomeprazole (40 mg twice daily), amoxicillin (1 g twice daily) and clarithromycin (500 mg twice daily). On the other hand, the second group was prescribed a 10-d course of modified bismuth quadruple therapy fortified with zinc carnosine: TT in addition to bismuth subcitrate (240 mg twice daily) and zinc carnosine (75 mg twice daily). A repeated 13C-urea breath test was done 4 wk after the completion of the eradication therapy.

RESULTS

Among the 92 subjects, 67.4% were males and 32.6% were females. There were no differences in demographic characteristics (age, body mass index, smoking history, previous antibiotics use and ethnicity) between the modified bismuth quadruple therapy group and TT group. The eradication rate was higher [93.5% (43/46)] in the modified bismuth quadruple therapy group compared to 69.6% (32/46) in the standard TT group (*P* = 0.003). Of the tested predictor variables, only nationality, smoking and therapy type were statistically significant. Besides dizziness, which was recorded in modified bismuth quadruple therapy group, there were no significant differences in side effects between the two groups.

CONCLUSION

Ten days of modified bismuth quadruple therapy fortified with zinc carnosine is superior to 14 d of conventional TT in eradicating *H. pylori* infection, with no additional significant adverse events.

**Key Words:** *Helicobacter pylori*; Polaprezinc; Bismuth; Peptic ulcer; Gastritis; Drug Resistance; Microbial

Ibrahim N, El Said H, Choukair A. Zinc carnosine-based modified bismuth quadruple therapy *vs* standard triple therapy for Helicobacter pylori eradication: A randomized controlled study. *World J Clin Cases* 2021; In press

**Core Tip:** High eradication failure rate of *Helicobacter pylori* (*H. pylori*) infection has been reported due to increasing antibiotic resistance. This necessitates the need for better alternative regimens. The present study revealed higher *H. pylori* eradication rate with the use of zinc carnosine-based modified bismuth quadruple therapy for 10 d than with 14 d of standard triple therapy.

**INTRODUCTION**

Since its first successful culture in the laboratory almost 40 years ago, *Helicobacter pylori* (*H. pylori*) infection and gastric diseases have been a source of debate among medical professionals and scientists[1,2]. This bacterium, which is among very few organisms that can survive in the human stomach, has gained much reputation, mostly as a harmful bacterium, based on its association with various gastroduodenal diseases[3]. *H. pylori* is a highly prevalent helical shaped gram-negative bacterium that colonizes and infects the human gastric mucosa in approximately more than 50% of the world’s population[4]. One conducted cross-sectional study in the United Arab Emirates revealed that the prevalence of *H. pylori* among healthy children and adults was 40%[5]. Infection can, at a minimum, cause gastritis and is a prominent etiologic agent of gastric and duodenal ulcer diseases, gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma[2,6,7]. The development of peptic ulcers arises in about 10%-20% of patients infected with *H. pylori*, while advancement to gastric cancer occurs in 1%-3% of cases[8].

Triple therapy (TT), which includes a proton pump inhibitor (PPI) and two antimicrobial agents (clarithromycin and amoxicillin or metronidazole) prescribed for 10 to 14 d, has been the standard first-line eradication therapy since 1996[9]. However, due to the increased rate of clarithromycin or metronidazole resistance, standard TT has been often ineffective in regions with high antibiotic resistance[10,11]. In fact, one systematic review and meta-analysis revealed a high resistance rate (≥ 15%) of *H. pylori* to clarithromycin and metronidazole in World Health Organization regions[12]. This has led to a detrimental effect on the efficacy of the triple treatment regimen, as its eradication response now falls considerably short between 50%-70%[13]. This is considered far below the minimal acceptable level of intention-to-treat (ITT) eradication rate (> 80%) as recommended by Maastricht guidelines[14]. As a result, four-drug regimens (quadruple, sequential, concomitant and hybrid) and levofloxacin-containing therapies have been studied with variable success[15,16]. Later on, a bismuth based treatment, now known as bismuth quadruple therapy, was suggested as an alternative initial therapy option, especially in regions where high rates of antibiotic resistance exist[13].

Studies have shown that the efficacy of bismuth in *H. pylori* treatment regimens is mainly associated with its bactericidal effect against *H. pylori*[17]. Various means that aid bismuth to exert such a role have been proposed[18]. Ultrastructural studies showed that bismuth bind the bacterial wall and periplasmic membrane, thus forming complexes[19]. Moreover, experiments revealed that bismuth is capable of inhibiting various enzymes of *H. pylori* such as urease, phospholipase and catalase[20]. One other mechanism through which bismuth exerts its anti-*H. pylori* actions is by inhibiting the pathogen’s protein and adenosine triphosphate synthesis and preventing its adherence to the gastric mucosa[21]. Bismuth compounds also protect the gastric mucosa and aid in ulcer healing[22]. No resistance of strains of *H. pylori* to bismuth has been reported yet.

Another potential adjuvant therapy that has been evaluated to enhance the eradication of *H. pylori* is polaprezinc (PZ). PZ, a chelated compound composed of L-carnosine and zinc, is a mucosal protective agent[23] that has been used worldwide as a treatment for ulcers[24]. PZ prevents the formation of gastric mucosal lesions and mucosal cell damage induced by *H. pylori*–associated gastritis in a dose-dependent manner[25,26]. This role has been attributable to various properties possessed by PZ such as stimulating the production of mucus, exerting its stabilizing-membrane activity and having an antioxidant action[27-30]. Moreover, some studies revealed that PZ led to an improvement in eradication rates of *H. pylori*[31,32] by inhibiting the growth of *H. pylori*, in addition to impeding its urease activity and adhesion to gastric mucin.

We, hereby, present a study that compares the eradication responses of *H. pylori* obtained from a standard TT regimen *vs* a modified one that constitutes a standard TT regimen enforced by two adjuvants: Bismuth subcitrate and the nutritional supplement zinc carnosine (modified bismuth quadruple therapy or MBQT).

**MATERIALS AND METHODS**

***Study design***

The present study was a prospective, open-label, randomized, controlled trial performed between 2018-2019. Physicians were not blinded to which treatment the subjects received. The patient population comprised 92 consecutive outpatients who presented to outpatient clinic with dyspepsia symptoms and were found to have *H. pylori* infection. *H. pylori* infection was diagnosed by 13C urea breath test (UBT) and reassessed 4 wk after the completion of the assigned treatment. The exclusion criteria were: Age < 18 years, existence of severe concomitant diseases, use of medications effective against *H. pylori* such as bismuth compounds, PPIs, or antibiotics during the last 3 mo, history of gastroduodenal surgery, pregnancy or lactation, chronic corticosteroid or nonsteroidal anti-inflammatory drug use, history of allergy to PPI, macrolides or penicillin, alcohol abuse or drug addiction. Prior to enrolment, a written informed consent was obtained from all patients. This study was approved by the Clinical Research Ethics Committee of NMC specialty hospital.

***Clinical trial***

The enrolled patients were randomized by drawing a sealed envelope that contained pre-assigned treatment instructions. They were allocated to one of the following two groups. Group A (TT group) received esomeprazole 40 mg, clarithromycin 500 mg and amoxicillin 1 g and all the medications were given twice daily for subsequent 14 d. On the other hand, group B (MBQT group) received zinc carnosine (gastrozin) 75 mg and bismuth subcitrate 240 mg in combination with esomeprazole 40 mg, clarithromycin 500 mg and amoxicillin 1 g. All the later medications were given twice daily for subsequent 10 d. Compliance with medication was checked immediately after stopping the treatment by counting the number of returned pills. Four weeks after cessation of the eradication therapy, a repeated UBT was done.

***Outcomes and statistical analysis***

All data entry and statistical analyses were carried out using SPSS version 26.0 for Windows (SPSS, Armonk, NY, United States). The cure rate was then calculated for each arm. Chi-square test, Fisher’s exact test and independent-samples *T*-test were used to compare the major outcomes between these groups. *H. pylori* cure rate was evaluated by per protocol (PP) analysis. PP analysis included all patients who took at least 80% of each study medication as prescribed and returned for assessment of *H. pylori* cure. Multivariable analysis adjusted for sex, age, body mass index, smoking habits, previous antibiotics intake and ethnicity was performed. A *P*-value less than 0.05 was considered statistically significant.

**RESULTS**

In this study, there were a total of 92 subjects of which 62 (67.4%) were males and 30 (32.6%) were females. Ages ranged from 19 to 56 years (mean of 31.88 ± 8.09 years). Most patients (60.9%) were Asian. This was followed by Arab (28.3%) and African (10.9%). Most subjects (81.5%) were non-smokers. Body mass index ranged from 17.20 to 43.70 kg/m2 (mean of 26.37 ± 4.12 kg/m2). Table 1 shows the demographic characteristics of the two tested groups. Of the two types of therapy, there were 46 (50%) individuals in the MBQT group and 46 (50%) in the TT group (*P* = 0.003). Among subjects in the MBQT group, 43 tested negative on the repeated UBT test and 3 tested positive. In the TT group, 32 tested negative and 14 tested positive (Figure 1).

Binary logistic regression models were fitted in order to determine the efficacy of the MBQT in the eradication of *H. pylori* compared with the standard TT. All assumptions of logistic regression were met. Of the predictor variables, only three were statistically significant: Nationality, smoking and therapy type (Table 2).

Patients who received TT were 11 times more likely to have a positive UBT than those who received MBQT [adjusted odds ratio (aOR) = 11.44, *P* = 0.004, 95% confidence interval (CI): 2.179-60.07]. Moreover, Arabs were more likely to obtain negative UBT than Asians (aOR = 0.19, *P* = 0.019, 95% CI 0.019-0.696). Furthermore, smoking seemed to increase the odds of persistent *H. pylori* by 5-fold (aOR = 5.12, *P* = 0.049, 95% CI: 1.005-26.097).

There were some adverse events that occurred in each of the two types of therapies. In the MBQT group, there was one occurrence (2.17% each) of nausea, abdominal pain and fatigue and three occurrences (6.52%) of dizziness. On the other hand, the TT group reported one occurrence (2.17% each) of nausea, diarrhea and fatigue and two occurrences (4.34%) of abdominal pain (Figure 2).

**DISCUSSION**

In this prospective study, we aimed to tackle the issue of increased failure rate of standard antimicrobial therapies by combining the benefits and positive effects of both bismuth compound and zinc carnosine in a single regimen protocol. The latter was used to enhance the effect of antimicrobial therapy in eradicating *H. pylori* infection, while at the same time maintaining a safe profile of the regimen with good patient compliance to the treatment course. In fact, our study was able to show that adding bismuth subcitrate and zinc carnosine to the standard therapy was associated with an increase in negative UBT results, leading to a better eradication rate of *H. pylori* in that subgroup of patients.

The recent Kyoto global consensus categorized *H. pylori*-induced gastritis as an infectious disease and recommended performing *H. pylori* eradication before premalignant changes develop to prevent gastric carcinogenesis[33]. However, the previously assigned first-line choice for *H. pylori* eradication, which is a clarithromycin-based TT, has become asubject of argument in the medical field due to the worldwide growing resistance to clarithromycin, especially in developing countries[13]. In fact, several regimens have been proposed to overcome this critical concern. One of these regimens that added bismuth as adjuvant to other antimicrobial agents was found to exert synergistic effect that improved eradication rates by almost 30%[34]. In another clinical trial in China, a bismuth-quadruple therapy achieved a 92.7% eradication of *H. pylori* by ITT analysis[35]. Our study confirms the latter reports on a better eradication rate of the infection with MBQT. Recent studies from other countries suggested that the use of B-quadruple therapy is remarkably effective even in the presence of antibiotic resistance and prior treatment failures[36,37]. On the other hand, a 10-d course of quadruple therapy, consisting of the mucoprotective agent sofalcone added to rabeprazole, amoxicillin and clarithromycin, demonstrated satisfactory treatment outcome with *H. pylori* eradication rate being not less than 94% on the PP basis[31]. In addition to this, the concomitant use of PZ with TT regimen had previously shown promise in increasing the eradication rate of *H. pylori* infection. In 1999, Kashimura *et al*[31] revealed that *H. pylori* eradication rate can be significantly increased from 77.4% to 94.3% when PZ is added to the TT. In a more recent study, Tan *et al*[38] (2017) reported that the combined use of PZ with TT improved the eradication rate of *H. pylori* by 18.4% (ITT analysis) and 19.7% (PP analysis). This has been further validated by the results of our study where eradication rates were higher by 23.9% in MBQT group in comparison with that of TT group. Indeed, this points out the added benefit of using PZ concomitantly with bismuth in increasing *H. pylori* eradication rates. However, further studies are needed to compare and evaluate the efficacy of PZ solely *vs* when combined with bismuth for the eradication of *H. pylori*.

Many factors may affect eradication efficacy such as the physical structure of the patient, smoking habits, adherence to the prescribed regimen, genetic predisposition of cytochrome p450 2C19, which metabolizes PPIs, and frequency of strains resistant to antimicrobials[39,40]. In the present study, there were no significant differences in the baseline characteristics among the trial arms. Although the susceptibility of *H. pylori* to antibiotics was not assessed in our study, the risk of antibiotic resistance was minimized by excluding patients who had taken previous treatments effective against the organism. In addition to that, our study also showed that being a smoker increased the risk of treatment failure by 5-fold, which comes in concordance with other studies revealing the negative effect of smoking on the eradication rate[41,42]. Another interesting finding was ethnic variability regarding eradication success, where being of Arabic ethnicity increased the odds of eradication success. This could be pertained to ethnic disparities in dietary intake. Hołubiuk *et al*[43] revealed promising data regarding the anti*-H. pylori* activity of certain food products present in fruits and vegetables, which is highly consumed in the Middle East[44]. Moreover, another possible factor that may account for such difference is the variability of antibiotics resistant strains among ethnicities or countries due to antibiotics abuse and use. However, the small sample size of our studied population questions the true significance of this finding.

In terms of safety, there has been concerns for bismuth induced neurotoxicity, mostly associated with chronic use[45].However, in our trial, no bismuth related adverse effects were noted in the MBQT group. In addition, all-cause adverse events in both groups were tolerable and minor and had no influence on patient compliance.

By performing in depth analysis of our study, several limitations were found. Firstly, our study would have benefited from an analysis of *H. pylori* cultures and antibiograms. This was not feasible for technical and financial causes; hence, the exact role of antibiotic resistance (namely to clarithromycin) in eradication failure could not be evaluated. Another limitation was the study’s lack of double blinding and long-term follow-up period. A third technical limitation was the restricted availability of bismuth, which led to a smaller sample size than what we initially planned. Finally, the information on prior macrolide use was collected from patients using a questionnaire and may have therefore been subject to recall bias.

**CONCLUSION**

In conclusion, our study provides more evidence that 10-d modified B-quadruple therapy is a safe and effective therapeutic option for eradicating *H. pylori* infection. This significant rate of success should promote such therapies to be considered as first line option in place of the old and declining TT protocol.

**ARTICLE HIGHLIGHTS**

***Research background***

The rate of resistance of *Helicobacter pylori* *(H. pylori)* infection has been increasing worldwide. It is necessary to consider new alternatives to overcome the failure of *H. pylori* eradication rate.

***Research motivation***

There is shortage in reports on whether zinc carnosine is effective against *H. pylori* eradication.

***Research objectives***

Investigate the effect of triple therapy (TT) *vs* modified bismuth quadruple therapy against *H. pylori* eradication rate.

***Research methods***

Ninety-two patients with dyspepsia symptoms and positive 13C-urea breath test were randomly assigned in to the following two groups: TT group treated for 14 d using esomeprazole (40 mg twice daily), amoxicillin (1 g twice daily) and clarithromycin (500 mg twice daily). On the other hand, the modified bismuth quadruple therapy fortified with zinc carnosine was prescribed a 10-d of TT in addition to bismuth subcitrate (240 mg twice daily) and zinc carnosine (75 mg twice daily). A 13C-urea breath test was repeated after 4 wk from the completion of the eradication therapy.

***Research results***

The eradication rate was higher in the modified bismuth quadruple therapy group compared to that of the standard TT group (*P* = 0.003).

***Research conclusions***

Ten-day modified bismuth quadruple therapy is a safe and effective regimen for eradicating *H. pylori* infection.

***Research perspectives***

The first-line therapy for *H. pylori* eradication should be re-evaluated. Alternative regimens with higher eradication of *H. pylori* should be further investigated.

**REFERENCES**

1 **Marshall BJ**, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet* 1984; **1**: 1311-1315 [PMID: 6145023 DOI: 10.1016/s0140-6736(84)91816-6]

2 **Dunn BE**, Cohen H, Blaser MJ. Helicobacter pylori. *Clin Microbiol Rev* 1997; **10**: 720-741 [PMID: 9336670 DOI: 10.1128/CMR.10.4.720]

3 **Cover TL**, Blaser MJ. Helicobacter pylori and gastroduodenal disease. *Annu Rev Med* 1992; **43**: 135-145 [PMID: 1580578 DOI: 10.1146/annurev.me.43.020192.001031]

4 **Eusebi LH**, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. *Helicobacter* 2014; **19 Suppl 1**: 1-5 [PMID: 25167938 DOI: 10.1111/hel.12165]

5 **Leja M,** Grinberga-Derica I, Bilgilier C, Steininger C. Review: Epidemiology of Helicobacter pylori infection. *Helicobacter* 2019; **24 Suppl 1**: e12635 [PMID: 31486242 DOI: 10.1111/hel.12635]

6 **Blaser MJ**. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. *J Infect Dis* 1990; **161**: 626-633 [PMID: 2181029 DOI: 10.1093/infdis/161.4.626]

7 **Peek RM Jr**, Crabtree JE. Helicobacter infection and gastric neoplasia. *J Pathol* 2006; **208**: 233-248 [PMID: 16362989 DOI: 10.1002/path.1868]

8 **Noto JM**, Peek RM Jr. Helicobacter pylori: an overview. *Methods Mol Biol* 2012; **921**: 7-10 [PMID: 23015485 DOI: 10.1007/978-1-62703-005-2\_2]

9 **Chey WD**, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. *Am J Gastroenterol* 2007; **102**: 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]

10 **Graham DY**, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. *Gut* 2010; **59**: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]

11 **Papastergiou V**, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Past, present and future. *World J Gastrointest Pathophysiol* 2014; **5**: 392-399 [PMID: 25400982 DOI: 10.4291/wjgp.v5.i4.392]

12 **Savoldi A**, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. *Gastroenterology* 2018; **155**: 1372-1382.e17 [PMID: 29990487 DOI: 10.1053/j.gastro.2018.07.007]

13 **Malfertheiner P,** Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646–664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

14 **Malfertheiner P**, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. *Gut* 2007; **56**: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]

15 **Vaira D**, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. *Ann Intern Med* 2007; **146**: 556-563 [PMID: 17438314 DOI: 10.7326/0003-4819-146-8-200704170-00006]

16 **Liou JM,** Lin JT, Chang CY, Chen MJ, Cheng TY, Lee YC, Chen CC, Sheng WH, Wang HP, Wu MS. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. *Gut* 2010; **59**: 572-578 [PMID: 20427390 DOI: 10.1136/gut.2009.198309]

17 **Alkim H,** Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. *Am J Ther* 2017; **24**: e751-e757 [PMID: 26808355 DOI: 10.1097/MJT.0000000000000389]

18 **Ge R**, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. *Metallomics* 2012; **4**: 239-243 [PMID: 22358069 DOI: 10.1039/c2mt00180b]

19 **Keogan DM**, Griffith DM. Current and potential applications of bismuth-based drugs. *Molecules* 2014; **19**: 15258-15297 [PMID: 25251194 DOI: 10.3390/molecules190915258]

20 **Lambert JR**, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. *Aliment Pharmacol Ther* 1997; **11 Suppl 1**: 27-33 [PMID: 9146788 DOI: 10.1046/j.1365-2036.11.s1.13.x]

21 **McColm AA**, McLaren A, Klinkert G, Francis MR, Connolly PC, Grinham CJ, Campbell CJ, Selway S, Williamson R. Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrate-ranitidine admixture. *Aliment Pharmacol Ther* 1996; **10**: 241-250 [PMID: 8791946 DOI: 10.1111/j.0953-0673.1996.00241.x]

22 **Tanaka S**, Guth PH, Paulsen G, Kaunitz JD. Gastroprotective effect of ranitidine bismuth citrate is associated with increased mucus bismuth concentration in rats. *Gut* 1996; **39**: 164-171 [PMID: 8977335 DOI: 10.1136/gut.39.2.164]

23 **Vallee BL**, Falchuk KH. The biochemical basis of zinc physiology. *Physiol Rev* 1993; **73**: 79-118 [PMID: 8419966 DOI: 10.1152/physrev.1993.73.1.79]

24 **Hewlings S**, Kalman D. A Review of Zinc-L-Carnosine and Its Positive Effects on Oral Mucositis, Taste Disorders, and Gastrointestinal Disorders. *Nutrients* 2020; **12** [PMID: 32121367 DOI: 10.3390/nu12030665]

25 **Ishihara R**, Iishi H, Sakai N, Yano H, Uedo N, Narahara H, Iseki K, Mikuni T, Ishiguro S, Tatsuta M. Polaprezinc attenuates Helicobacter pylori-associated gastritis in Mongolian gerbils. *Helicobacter* 2002; **7**: 384-389 [PMID: 12485126 DOI: 10.1046/j.1523-5378.2002.00114.x]

26 **Handa O**, Yoshida N, Tanaka Y, Ueda M, Ishikawa T, Takagi T, Matsumoto N, Naito Y, Yoshikawa T. Inhibitory effect of polaprezinc on the inflammatory response to Helicobacter pylori. *Can J Gastroenterol* 2002; **16**: 785-789 [PMID: 12464972 DOI: 10.1155/2002/631070]

27 **Yoshikawa T,** Naito Y, Tanigawa T, Yoneta T, Yasuda M, Ueda S, Oyamada H, Kondo M. Effect of zinc-carnosine chelate compound (Z-103), a novel antioxidant, on acute gastric mucosal injury induced by ischemia-reperfusion in rats. *Free Radic Res Commun* 1991; **14**: 289-296 [PMID: 1874458 DOI: 10.3109/10715769109088958]

28 **Cho CH**, Luk CT, Ogle CW. The membrane-stabilizing action of zinc carnosine (Z-103) in stress-induced gastric ulceration in rats. *Life Sci* 1991; **49**: PL189-PL194 [PMID: 1943472 DOI: 10.1016/0024-3205(91)90321-2]

29 **Arakawa T,** Satoh H, Nakamura A, Nebiki H, Fukuda T, Sakuma H, Nakamura H, Ishikawa M, Seiki M, Kobayashi K. Effects of zinc L-carnosine on gastric mucosal and cell damage caused by ethanol in rats. Correlation with endogenous prostaglandin E2. *Dig Dis Sci* 1990; **35**: 559-566 [PMID: 2331952 DOI: 10.1007/bf01540402]

30 **Ohata S**, Moriyama C, Yamashita A, Nishida T, Kusumoto C, Mochida S, Minami Y, Nakada J, Shomori K, Inagaki Y, Ohta Y, Matsura T. Polaprezinc Protects Mice against Endotoxin Shock. *J Clin Biochem Nutr* 2010; **46**: 234-243 [PMID: 20490319 DOI: 10.3164/jcbn.09-125]

31 **Kashimura H**, Suzuki K, Hassan M, Ikezawa K, Sawahata T, Watanabe T, Nakahara A, Mutoh H, Tanaka N. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. *Aliment Pharmacol Ther* 1999; **13**: 483-487 [PMID: 10215732 DOI: 10.1046/j.1365-2036.1999.00510.x]

32 **Sakae K**, Yanagisawa H. Oral treatment of pressure ulcers with polaprezinc (zinc L-carnosine complex): 8-week open-label trial. *Biol Trace Elem Res* 2014; **158**: 280-288 [PMID: 24691900 DOI: 10.1007/s12011-014-9943-5]

33 **Sugano K**, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. *Gut* 2015; **64**: 1353-1367 [PMID: 26187502 DOI: 10.1136/gutjnl-2015-309252]

34 **Dore MP**, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. *Gut* 2016; **65**: 870-878 [PMID: 26848181 DOI: 10.1136/gutjnl-2015-311019]

35 **Liu KS,** Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong SY, Leung WK. Ten day sequential vs 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. *Gut* 2014; **63**: 1410-1415 [PMID: 24295850 DOI: 10.1136/gutjnl-2013-306120]

36 **Ciccaglione AF**, Tavani R, Grossi L, Cellini L, Manzoli L, Marzio L. Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third-Line Treatment of Helicobacter pylori Infection: Two Pilot Studies. *Helicobacter* 2016; **21**: 375-381 [PMID: 26807668 DOI: 10.1111/hel.12296]

37 **Muller N**, Amiot A, Le Thuaut A, Bastuji-Garin S, Deforges L, Delchier JC. Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains. *Clin Res Hepatol Gastroenterol* 2016; **40**: 517-524 [PMID: 26850363 DOI: 10.1016/j.clinre.2015.12.012]

38 **Tan B**, Luo HQ, Xu H, Lv NH, Shi RH, Luo HS, Li JS, Ren JL, Zou YY, Li YQ, Ji F, Fang JY, Qian JM. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. *PLoS One* 2017; **12**: e0175625 [PMID: 28407007 DOI: 10.1371/journal.pone.0175625]

39 **Suzuki T**, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R, Tajima K. Smoking increases the treatment failure for Helicobacter pylori eradication. *Am J Med* 2006; **119**: 217-224 [PMID: 16490464 DOI: 10.1016/j.amjmed.2005.10.003]

40 **Miyoshi M**, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, Tsuji T. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. *J Gastroenterol Hepatol* 2001; **16**: 723-728 [PMID: 11446878 DOI: 10.1046/j.1440-1746.2001.02526.x]

41 **Camargo MC**, Piazuelo MB, Mera RM, Fontham ET, Delgado AG, Yepez MC, Ceron C, Bravo LE, Bravo JC, Correa P. Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia. *Acta Gastroenterol Latinoam* 2007; **37**: 238-245 [PMID: 18254262]

42 **Itskoviz D**, Boltin D, Leibovitzh H, Tsadok Perets T, Comaneshter D, Cohen A, Niv Y, Levi Z. Smoking increases the likelihood of Helicobacter pylori treatment failure. *Dig Liver Dis* 2017; **49**: 764-768 [PMID: 28427781 DOI: 10.1016/j.dld.2017.03.010]

43 **Hołubiuk Ł**, Imiela J. Diet and *Helicobacter pylori* infection. *Prz Gastroenterol* 2016; **11**: 150-154 [PMID: 27713775 DOI: 10.5114/pg.2016.61487]

44 Garduno SD. Dietary Patterns and Food Culture in the Middle East. *EC Nutr* 2015; **2**: 318–327

45 **Slikkerveer A**, de Wolff FA. Pharmacokinetics and toxicity of bismuth compounds. *Med Toxicol Adverse Drug Exp* 1989; **4**: 303-323 [PMID: 2682129 DOI: 10.1007/BF03259915]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Clinical Research Ethics Committee of NMC specialty hospital.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 25, 2021

**First decision:** July 27, 2021

**Article in press:**

**Specialty type:** Gastroenterology and Hepatology

**Country/Territory of origin: Lebanon**

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chattopadhyay S **S-Editor:** Chang KL **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**

****

**Figure 1 Eradication rate of *Helicobacter pylori* infection by therapy type.** MBGT: Modified bismuth quadruple therapy; TT: Triple therapy; UBT: Urea breath test.



**Figure 2 Reported adverse effects in each treatment group.** MBGT: Modified bismuth quadruple therapy; TT: Triple therapy.

**Table 1 Demographic characteristics of the study population**

|  |  |  |
| --- | --- | --- |
| **Variable** | **MBQT (*n* = 46)** | **TT (*n* = 46)** |
|  | (mean ± SD) |
| Age | 35.83 ± 7.41 yr | 27.93 ± 6.78 yr |
| Mean body mass index | 26.08 ± 4.57 kg/m2 | 26.67 ± 3.65 kg/m2 |
|  | %(*n*) |
| Sex |  |
| Female | 32.6% (15) | 32.6% (15) |
| Male | 67.4% (31) | 67.4% (31) |
| Patients who smoke | 17.4% (8) | 19.6% (9) |
| Patients with previous antibiotics intake | 17.4 % (8) | 4.3% (2) |
| Ethnicity  |  |  |
| African | 10.9% (5) | 10.9% (5) |
| Araba | 26.1% (12) | 30.4% (14) |
| Asianb | 63% (29) | 58.7% (27) |

aArab: The included countries were the United Arab Emirates, Lebanon, Syria, Iraq, Jordan and Egypt. bAsian: Mainly from east Asia; the included countries were India, Philippines and Pakistan. MBQT: modified bismuth quadruple therapy; SD: Standard deviation.

**Table 2 Binary logistic regression model predicting positive urea breath test**

|  |  |  |  |
| --- | --- | --- | --- |
|  | ***P*** | **aOR** | **95% CI** |
| **Lower** | **Upper** |
| Age | 0.662 | 1.020 | 0.93 | 1.12 |
| Sex, female | 0.367 | 1.874 | 0.48 | 7.33 |
| Therapy (TT) | 0.004 | 11.440 | 2.18 | 60.07 |
| Smoking | 0.049 | 5.120 | 1.01 | 26.1 |
| Nationality (Asian)a  | 0.049 |  |  |  |
| Nationality (African) | 0.368 | 0.351 | 0.036 | 3.43 |
| Nationality (Arabs) | 0.019 | 0.114 | 0.019 | 0.67 |
| History of antibiotics | 0.294 | 3.15 | 0.37 | 26.86 |

a: Reference; TT: Triple therapy; aOR: Adjusted odds ratio; CI: Confidence interval.